Background:Mizoribine(MZR)is a selective inhibitor of inosine monophosphate dehydrogenase,a key enzyme in the pathway responsible for de novo synthesis of guanine nucleotides.As an immunosuppressant,MZR has been used ...Background:Mizoribine(MZR)is a selective inhibitor of inosine monophosphate dehydrogenase,a key enzyme in the pathway responsible for de novo synthesis of guanine nucleotides.As an immunosuppressant,MZR has been used successfully without any serious adverse effects in the treatment of renal diseases in children as well as adults.Besides its immunosuppressive effect,MZR has been reported to ameliorate tubulointerstitial fibrosis in rats via suppression of macrophage infiltration.Data Sources:In this review,we summarize reported possible benefits of MZR in the treatment of pediatric-onset glomerular disease.Results:We recently observed that MZR itself selectively attenuates the expression of monocyte chemoattractant protein-1 at both the mRNA and protein levels in human mesangial cells.Since MZR binds specifically to 14-3-3 proteins and heat shock protein 60,both of which are reportedly expressed in inflamed glomeruli,MZR may bind directly to inflamed glomerular cells,thereby possibly preventing progressive damage from glomerulonephritis through a suppressive effect on activated macrophages and intrinsic renal cells.Moreover,it has recently been reported that MZR directly prevents podocyte injury through correction of the intracellular energy balance and nephrin biogenesis in cultured podocyte and rat models,suggesting a direct anti-proteinuric effect of MZR.Conclusions:These beneficial mechanisms of action of MZR as well as its immunosuppressive effect would warrant its use in the treatment of pediatric-onset glomerular disease.Although further studies remain to be done,we believe that MZR may be an attractive treatment of choice for children with glomerular diseases from a histologic as well as clinical standpoint.展开更多
基金supported by grants-in-aid for Science from the Ministry of Education,Culture,Sports,Science and Technology of Japan(TH and IT).
文摘Background:Mizoribine(MZR)is a selective inhibitor of inosine monophosphate dehydrogenase,a key enzyme in the pathway responsible for de novo synthesis of guanine nucleotides.As an immunosuppressant,MZR has been used successfully without any serious adverse effects in the treatment of renal diseases in children as well as adults.Besides its immunosuppressive effect,MZR has been reported to ameliorate tubulointerstitial fibrosis in rats via suppression of macrophage infiltration.Data Sources:In this review,we summarize reported possible benefits of MZR in the treatment of pediatric-onset glomerular disease.Results:We recently observed that MZR itself selectively attenuates the expression of monocyte chemoattractant protein-1 at both the mRNA and protein levels in human mesangial cells.Since MZR binds specifically to 14-3-3 proteins and heat shock protein 60,both of which are reportedly expressed in inflamed glomeruli,MZR may bind directly to inflamed glomerular cells,thereby possibly preventing progressive damage from glomerulonephritis through a suppressive effect on activated macrophages and intrinsic renal cells.Moreover,it has recently been reported that MZR directly prevents podocyte injury through correction of the intracellular energy balance and nephrin biogenesis in cultured podocyte and rat models,suggesting a direct anti-proteinuric effect of MZR.Conclusions:These beneficial mechanisms of action of MZR as well as its immunosuppressive effect would warrant its use in the treatment of pediatric-onset glomerular disease.Although further studies remain to be done,we believe that MZR may be an attractive treatment of choice for children with glomerular diseases from a histologic as well as clinical standpoint.
